
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc presents a favorable outlook due to its robust pipeline of therapies aimed at activating the immune system to combat cancer, supported by in-house capabilities including cGMP manufacturing and clinical operations. The compassionate use of the company’s antibody candidates, botensilimab and balstilimab, is anticipated to create an additional revenue stream while generating real-world clinical evidence to bolster their applications. Furthermore, positive early regulatory sentiment regarding these therapies in indications such as triple-negative breast cancer and microsatellite-stable colorectal cancer contributes to the overall growth potential of the company.
Bears say
Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. These include potential safety signals arising from clinical or preclinical programs, lower-than-expected efficacy from trials, and increased competition from other treatments. Additionally, concerns regarding regulatory challenges, financing needs, and intellectual property protection further compound the uncertainty surrounding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares